|
|
Volumn 15, Issue 2, 2015, Pages 165-169
|
|
Lessons for tumor biomarker trials: Vicious cycles, scientific method & developing guidelines
|
|
Author keywords
biomarker validation; breast cancer; clinical validity; companion diagnostics; oncology; regulatory
|
|
Indexed keywords
ANTIESTROGEN;
CA 15-3 ANTIGEN;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
TRASTUZUMAB;
TUMOR MARKER;
ANTINEOPLASTIC AGENT;
BREAST CANCER;
BREAST METASTASIS;
CIRCULATING TUMOR CELL;
CLINICAL RESEARCH;
CLINICAL TRIAL (TOPIC);
CULTURAL ANTHROPOLOGY;
EVIDENCE BASED PRACTICE;
EXPERIMENTAL THERAPY;
GENOMICS;
HEALTH;
HEALTH CARE QUALITY;
HORMONAL THERAPY;
HUMAN;
LAW;
NORTH AMERICAN;
ONCOLOGY;
OVERALL SURVIVAL;
PATIENT CARE;
PRACTICE GUIDELINE;
PREDICTION;
PROSTATE CANCER;
PUBLICATION;
REIMBURSEMENT;
RETROSPECTIVE STUDY;
REVIEW;
SOCIAL CLASS;
BREAST NEOPLASMS;
FEMALE;
INTERVIEW;
METABOLISM;
MOLECULARLY TARGETED THERAPY;
PATHOLOGY;
PERSONALIZED MEDICINE;
TRANSLATIONAL RESEARCH;
TUMOR EMBOLISM;
ANTINEOPLASTIC AGENTS;
BREAST NEOPLASMS;
FEMALE;
HUMANS;
INDIVIDUALIZED MEDICINE;
MOLECULAR TARGETED THERAPY;
NEOPLASTIC CELLS, CIRCULATING;
PRACTICE GUIDELINES AS TOPIC;
TRANSLATIONAL MEDICAL RESEARCH;
TUMOR MARKERS, BIOLOGICAL;
|
|
EID: 84921373038
PISSN: 14737159
EISSN: 17448352
Source Type: Journal
DOI: 10.1586/14737159.2015.991893 Document Type: Review |
|
Times cited : (13)
|
|
References (4)
|
